23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › NEKTAR THERAPEUTICS › 2023-2024

NEKTAR THERAPEUTICS 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and NEKTAR THERAPEUTICS’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 124Asset managers, any item
  • 392Fund votes
  • June 5, 2024Meeting date

Results at a glance

Meeting of June 5, 2024: 6 items on NEKTAR THERAPEUTICS’s Form 8-K, filed June 6, 2024: 3 elected · 3 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Two Seas Capital LP (13F, 9.8%, as of September 30, 2026)

Explore NEKTAR THERAPEUTICS in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by NEKTAR THERAPEUTICS

These tallies are NEKTAR THERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

NEKTAR THERAPEUTICS — official shareholder meeting results, meeting held June 5, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jeff Ajer 89,572,5925,310,7525,112,487 --46,683,689 94%Elected—
Elect Director: Robert B. Chess 87,385,0927,518,9845,091,755 --46,683,689 92%Elected—
Elect Director: Roy A. Whitfield 85,885,2908,993,5825,116,959 --46,683,689 91%Elected—
2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares 86,500,5067,507,0375,988,288 --46,683,689 92%Approved—
3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 139,098,1191,556,5086,024,893 --0 99%Approved—
4. Proposal to approve the non-binding advisory resolution regarding our executive compensation 87,037,1786,730,7486,227,905 --46,683,689 93%Approved—

Source: NEKTAR THERAPEUTICS, Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.

How asset managers voted at the NEKTAR THERAPEUTICS 2023-2024 meeting

124 asset managers disclosed a vote on at least one NEKTAR THERAPEUTICS item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Jeff Ajer

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 89,572,592AGAINST: 5,310,752
Details: description as filed, official tally, votes by 20 asset managers

Description as filed by funds: Election of Directors: Jeff Ajer

NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Jeff Ajer”): 89,572,592 for, 5,310,752 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 23,712,753 for, 219,719 against.

FOR
FOR: 23,712,753AGAINST: 219,719
Largest asset managers voting on “Election of Directors: Jeff Ajer” at NEKTAR THERAPEUTICS, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,980,1940 00For
PRIMECAP Odyssey Funds6,305,7360 00For
Fidelity1,872,3880 00For
Charles Schwab1,129,1300 00For
BlackRock982,9040 00For
Invesco525,1250 00For
Nationwide277,4050 00For
Delaware/Macquarie256,3850 00For
Columbia Threadneedle0219,719 00Against
GuideStone87,5190 00For
Principal Exchange-Traded Funds50,4560 00For
Dimensional50,2630 00For
Jackson National39,7480 00For
Russell Investments32,9010 00For
Blackstone Alternative Investment Funds29,0000 00For
MASTER INVESTMENT PORTFOLIO28,2980 00For
Series Portfolios Trust24,8000 00For
Lincoln Financial15,6050 00For
Allianz14,3110 00For
John Hancock10,5850 00For

Elect Director: Robert B. Chess

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 87,385,092AGAINST: 7,518,984
Details: description as filed, official tally, votes by 20 asset managers

Description as filed by funds: Election of Directors: Robert B. Chess

NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Robert B. Chess”): 87,385,092 for, 7,518,984 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 23,582,241 for, 350,231 against.

FOR
FOR: 23,582,241AGAINST: 350,231
Largest asset managers voting on “Election of Directors: Robert B. Chess” at NEKTAR THERAPEUTICS, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,980,1940 00For
PRIMECAP Odyssey Funds6,305,7360 00For
Fidelity1,872,3880 00For
Charles Schwab1,129,1300 00For
BlackRock982,9040 00For
Invesco525,1250 00For
Nationwide277,4050 00For
Delaware/Macquarie256,3850 00For
Columbia Threadneedle0219,719 00Against
GuideStone87,5190 00For
Principal Exchange-Traded Funds50,4560 00For
Dimensional050,263 00Against
Jackson National039,748 00Against
Russell Investments32,9010 00For
Blackstone Alternative Investment Funds29,0000 00For
MASTER INVESTMENT PORTFOLIO28,2980 00For
Series Portfolios Trust24,8000 00For
Lincoln Financial015,605 00Against
Allianz014,311 00Against
John Hancock010,585 00Against

Elect Director: Roy A. Whitfield

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 85,885,290AGAINST: 8,993,582
Details: description as filed, official tally, votes by 20 asset managers

Description as filed by funds: Election of Directors: Roy A. Whitfield

NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Roy A. Whitfield”): 85,885,290 for, 8,993,582 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 22,931,243 for, 1,001,229 against.

FOR
FOR: 22,931,243AGAINST: 1,001,229
Largest asset managers voting on “Election of Directors: Roy A. Whitfield” at NEKTAR THERAPEUTICS, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,980,1940 00For
PRIMECAP Odyssey Funds6,305,7360 00For
Fidelity1,872,3880 00For
Charles Schwab1,129,1300 00For
BlackRock982,9040 00For
Invesco0525,125 00Against
Nationwide277,4050 00For
Delaware/Macquarie0256,385 00Against
Columbia Threadneedle0219,719 00Against
GuideStone87,5190 00For
Principal Exchange-Traded Funds50,4560 00For
Dimensional50,2630 00For
Jackson National39,7480 00For
Russell Investments32,9010 00For
Blackstone Alternative Investment Funds29,0000 00For
MASTER INVESTMENT PORTFOLIO28,2980 00For
Series Portfolios Trust24,8000 00For
Lincoln Financial15,6050 00For
Allianz14,3110 00For
John Hancock10,5850 00For

Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate…

Official resultCOMPENSATIONReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 86,500,506AGAINST: 7,507,037
Details: description as filed, official tally, votes by 23 asset managers

Description as filed by funds: To approve an amendment to our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 8,000,000 shares.

NEKTAR THERAPEUTICS’s own tally for this item (“2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares”): 86,500,506 for, 7,507,037 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares was approved with the following votes.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 23 asset managers below reported 23,742,503 for, 220,419 against.

FOR
FOR: 23,742,503AGAINST: 220,419
Largest asset managers voting on “To approve an amendment to our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate ” at NEKTAR THERAPEUTICS, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,980,1940 00For
PRIMECAP Odyssey Funds6,305,7360 00For
Fidelity1,872,3880 00For
Charles Schwab1,129,1300 00For
BlackRock982,9040 00For
Invesco525,1250 00For
Nationwide277,4050 00For
Delaware/Macquarie256,3850 00For
Columbia Threadneedle0219,719 00Against
GuideStone87,5190 00For
Principal Exchange-Traded Funds50,4560 00For
Dimensional50,2630 00For
Jackson National39,7480 00For
Russell Investments32,9010 00For
ALGERT GLOBAL LLC29,4300 00For
Blackstone Alternative Investment Funds29,0000 00For
MASTER INVESTMENT PORTFOLIO28,2980 00For
Series Portfolios Trust24,8000 00For
Lincoln Financial15,6050 00For
Allianz14,3110 00For
John Hancock10,5850 00For
MIDDLETON & CO INC/MA0700 00Against
GRIMES & COMPANY, INC.3200 00For

Proposal to approve the non-binding advisory resolution regarding our executive compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 87,037,178AGAINST: 6,730,748
Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).

NEKTAR THERAPEUTICS’s own tally for this item (“4. Proposal to approve the non-binding advisory resolution regarding our executive compensation”): 87,037,178 for, 6,730,748 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 20 asset managers voting on “To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).” at NEKTAR THERAPEUTICS, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,980,1940 00For
PRIMECAP Odyssey Funds6,305,7360 00For
Fidelity1,872,3880 00For
Charles Schwab1,129,1300 00For
BlackRock982,9040 00For
Invesco525,1250 00For
Nationwide277,4050 00For
Delaware/Macquarie256,3850 00For
Columbia Threadneedle219,7190 00For
GuideStone87,5190 00For
Principal Exchange-Traded Funds50,4560 00For
Dimensional50,2630 00For
Jackson National39,7480 00For
Russell Investments32,9010 00For
Blackstone Alternative Investment Funds29,0000 00For
MASTER INVESTMENT PORTFOLIO28,2980 00For
Series Portfolios Trust24,8000 00For
Lincoln Financial15,6050 00For
Allianz14,3110 00For
John Hancock10,5850 00For

Fund voting reports, all 20 managers: 23,932,472 for.

Institutional-manager reports: 107 asset managers voting on “To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).” at NEKTAR THERAPEUTICS, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP18,400,0000 00For
PRIMECAP MANAGEMENT CO/CA/6,926,3470 00For
Monaco Asset Management SAM00 5,030,8740Abstain
Citadel4,484,6230 00For
BlackRock4,047,5790 00For
Two Sigma3,537,1520 00For
Ensign Peak Advisors, Inc2,962,2250 00For
Renaissance2,952,7100 00For
Nantahala Capital Management, LLC2,819,0780 00For
ACADIAN ASSET MANAGEMENT LLC2,817,7530 00For
DE Shaw2,328,9080 00For
SAMLYN CAPITAL, LLC2,073,5850 00For
GEODE CAPITAL MANAGEMENT, LLC2,053,0850 00For
JACOBS LEVY EQUITY MANAGEMENT, INC1,233,0510 00For
Charles Schwab1,129,1300 00For
MARSHALL WACE, LLP01,099,131 00Against
UBS948,9300 00For
State Street690,2260 00For
Connor, Clark & Lunn Investment Management Ltd.575,8670 00For
Invesco525,1250 00For
Dimensional409,5250 00For
Northern Trust333,4370 00For
Woodline Partners LP270,2090 00For
AQR266,5790 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST256,3850 00For

Institutional-manager reports, all 107 managers: 63,297,723 for, 1,126,881 against, 5,030,874 abstained, 10,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 139,098,119AGAINST: 1,556,508

Prior year: 97.6% for (June 8, 2023 meeting) ▲ 1.3 pts

Details: description as filed, official tally, votes by 20 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

NEKTAR THERAPEUTICS’s own tally for this item (“3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 139,098,119 for, 1,556,508 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved with the following votes.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 23,932,472 for.

FOR
FOR: 23,932,472
Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fisc” at NEKTAR THERAPEUTICS, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,980,1940 00For
PRIMECAP Odyssey Funds6,305,7360 00For
Fidelity1,872,3880 00For
Charles Schwab1,129,1300 00For
BlackRock982,9040 00For
Invesco525,1250 00For
Nationwide277,4050 00For
Delaware/Macquarie256,3850 00For
Columbia Threadneedle219,7190 00For
GuideStone87,5190 00For
Principal Exchange-Traded Funds50,4560 00For
Dimensional50,2630 00For
Jackson National39,7480 00For
Russell Investments32,9010 00For
Blackstone Alternative Investment Funds29,0000 00For
MASTER INVESTMENT PORTFOLIO28,2980 00For
Series Portfolios Trust24,8000 00For
Lincoln Financial15,6050 00For
Allianz14,3110 00For
John Hancock10,5850 00For

Largest NEKTAR THERAPEUTICS shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 183,624,620 shares outstanding at the time of that meeting.

Fund voting reports: top NEKTAR THERAPEUTICS shareholders by shares voted on “To approve a non-binding advisory resolution regarding our executive compensation (a…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 6.52%
2PRIMECAP Odyssey Funds 3.43%
3Fidelity 1.02%
4Charles Schwab 0.61%
5BlackRock 0.54%
6Invesco 0.29%
7Nationwide 0.15%
8Delaware/Macquarie 0.14%
9Columbia Threadneedle 0.12%
10GuideStone 0.05%
Institutional-manager reports: top NEKTAR THERAPEUTICS shareholders by shares voted on “To approve a non-binding advisory resolution regarding our executive compensation (a…”, 2023-2024
#Asset manager % of shares outstanding
1Deep Track Capital, LP 10.02%
2PRIMECAP MANAGEMENT CO/CA/ 3.77%
3Monaco Asset Management SAM 2.74%
4Citadel 2.44%
5BlackRock 2.20%
6Two Sigma 1.93%
7Ensign Peak Advisors, Inc 1.61%
8Renaissance 1.61%
9Nantahala Capital Management, LLC 1.54%
10ACADIAN ASSET MANAGEMENT LLC 1.53%

Reported NEKTAR THERAPEUTICS holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

NEKTAR THERAPEUTICS holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
TCG Crossover GP II, LLC20,046,350 10.92%Proxy statement (DEF 14A), proxy filed April 26, 2024
Deep Track Capital, LP18,400,000 10.02%Proxy statement (DEF 14A), proxy filed April 26, 2024
The Vanguard Group12,042,873 6.56%Schedule 13G, filed February 13, 2024
Renaissance Technologies4,620,681 2.52%Form 13F, quarter ended March 31, 2024
Millennium Management2,984,545 1.63%Form 13F, quarter ended March 31, 2024
Howard W. Robin2,839,358 1.55%Proxy statement (DEF 14A), proxy filed April 26, 2024
D.E. Shaw2,548,990 1.39%Form 13F, quarter ended March 31, 2024
Two Sigma2,081,940 1.13%Form 13F, quarter ended March 31, 2024
Geode Capital2,053,085 1.12%Form 13F, quarter ended March 31, 2024
Jonathan Zalevsky, Ph.D.1,279,828 0.70%Proxy statement (DEF 14A), proxy filed April 26, 2024

Percentages above are of 183,624,620 shares outstanding, as reported by NEKTAR THERAPEUTICS on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At NEKTAR THERAPEUTICS's shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 124 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 392 separate fund positions. On the most widely held item on that ballot — To approve a non-binding advisory resolution regarding our executive compensation (a… — NEKTAR THERAPEUTICS's filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: NEKTAR THERAPEUTICS's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEKTAR THERAPEUTICS’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

NEKTAR THERAPEUTICS proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “NEKTAR THERAPEUTICS (NKTR) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/nektar-therapeutics/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.